HROW:NASDAQ
Harrow Inc
US$28.24
arrow_upward
+0.14%(+0.040) 1D
11월 3일, 오전 11시 17분 40초 GMT-5 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoHROW의 주요 통계 생성 중...
시가
US$28.21
고가
US$28.98
저가
US$28.09
시가총액
10.59억
평균 거래량
56.92만
거래량
10.68만
52주 최고가
US$54.85
52주 최저가
US$26.96
EPS
-US$1.00
베타
0.18
유통 주식수
3748.80만
직원 수
373
시가
US$28.21
고가
US$28.98
저가
US$28.09
시가총액
10.59억
평균 거래량
56.92만
거래량
10.68만
52주 최고가
US$54.85
52주 최저가
US$26.96
EPS
-US$1.00
베타
0.18
유통 주식수
3748.80만
직원 수
373
뉴스 기사
웹 소스 및 뉴스 파트너 제공
Yahoo! Finance Canada
·
1일 전
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?
Investing.com
·
1일 전
Harrow launches pharmacy platform for ophthalmic prescriptions
프로필
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
Harrow Inc에 관한 정보